Christopher Hite, Executive Vice President & Chairman, Partnering, on June 23, 2026, sold 150,000 shares in Royalty Pharma (RPRX) for $8,159,277. Following the Form 4 filing with the SEC, Hite has control over a total of 629,399 Class A ordinary shares of the company, with 70,000 shares held directly and 559,399 controlled indirectly.
SEC Filing: